That requires substantial investment and more dilution. I assume that may be the next step. Many members of this board are talking about Mr. Frost's involvement with Musclepharm. I think all of us need to understand that he got a deal. He is up 150% already in just two and a half months. Their Q4 sales indicate they have a long way to go and the valuation here is not attractive yet. With the capex of $20 million for manufacturing facility, I expect at least 30% more dilution on top of 8 million (fully diluted as of today) plus 2 million (for additional working capital as they may have lost a couple of millions in Q1, and for exec. compensation). 13-14 million shares with negative margin and flattening growth don't justify a valuation of more than 1x sales or say $70 million for the company. On a fully diluted basis, factoring in additional dilution for working capital and exec comp., sp over $8/ share is not justified. It may have a floor at $8.5 (the latest private placement price), but sp close to $10 does not offer any value here. There is a big difference between $27 million (not clarified in PR prior to release of 10K - they again played the same game) and $16.5 million (revealed in 10K). JMO.